Previous 10 | Next 10 |
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grants of non-statutory stock options to three new employees in connection with the commencement of their employ...
Sesen Bio (SESN): Q4 GAAP EPS of -$0.11 in-line.Cash, cash equivalents and restricted cash of $55.4M.Shares are up 4.2% PM.Press Release For further details see: Sesen Bio EPS in-line
Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 2021 1 Biologics License Application accepted by the FDA under Priority Review Marketing Authorization Application submitted in Europe with potential approval in early 2022 ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Follows U.S. FDA acceptance of the Biologics License Application under Priority Review Potential approval in Europe anticipated in early 2022 Significant commercial opportunity in Europe with projected peak revenue of $450M-$1.1B Sesen Bio (Nasdaq: SESN...
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company will host a conference call with Dr. Neal Shore, medical director of the Carolina Urologic Research Cen...
The FDA has provided Vicineum a priority review and an August 2021 PDUFA date. Following the headline, Sesen Bio's share price spiked to a new 52-week high. Now with an accelerated timeline and no AdCom, Sesen can prepare for a potential 2021 commercial launch. As a result, I am looki...
Sesen Bio's vicinium is targeting a form of NMIBC. Its chief competitor is adstiladril, and its current position with the FDA is a bit vague. This makes SESN a lot more attractive despite the recent price hike. For further details see: Sesen Bio: Problems Of Main Competi...
We propose a method for selling options that defies many myths around options selling. We analyzed options prices using statistical modelling and calculus to improve the "expected value" of trading versus conventional principles. Trades based on the criteria below are likely to wi...
Analysts Rate These Penny Stocks A Buy Right Now Finding the best penny stocks to buy right now can be a tall order. Not only are you dealing with noise in the market, but you’re also dealing with noise online. Set up any penny stock screener, and you’ll know what I...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...